Introduction: Telehealth delivery of diabetes self-management education and support (DSMES) has been widely adopted, yet lower participation is occurring in Hispanics who are disproportionately impacted by type 2 diabetes (T2D). Objective: Describe baseline and recruitment characteristics in an in-progress 3-way RCT that will compare the effectiveness of the Dulce Digital text messaging program and live in-person and virtual delivery (video telehealth classes) of Project Dulce DSMES in improving glycemic management of 150 Hispanic adults with T2D and A1C of ≥ 8%.

Methods: Descriptives statistics.

Results: There were 612 patients approached after EHR review. After recruitment screening, 69% did not meet the eligibility criteria, 8% were eligible and interested, and 24% were eligible but not interested. Reasons for disinterest were inconvenient class times (48%), concerns about study demands (e.g., length of study; 23%), distrust in research or health professionals (20%), lack of access to study location (6%), and limited access/knowledge of technology (2%). Enrolled participants (n=46) were on average 55 ± 11.3 years old, and 50% were female, 44% were born in the US, 70% had English as the preferred language, 54% were employed full-time, 49% had ≤ high school education, and 38% had an annual household income of ≥ $55K. Mean baseline A1C was 9.5% ± 1.5. Mean scores for Summary of Diabetes Self-Care Activities subscales were diet = 3.8 ± 1.9, exercise = 3.2 ± 2.4, glucose management = 3.8±2.6, and foot care = 3.5 ± 2.5 (range = 0-7); and Brief Measure of Healthy Literacy scale was 2.4 ± 1.5 (range = 0-10).

Conclusion: The average baseline A1C was high while mean scores for self-care behaviors were low-to-moderate and low for health literacy. Healthcare systems should consider addressing multilevel barriers to in-person and telehealth DSMES delivery to enhance engagement and improve diabetes outcomes, especially in high-risk Hispanic adults with limited health literacy.

Disclosure

E.N. San Diego: None. M. Ruiz: None. N. Orendain: None. K.L.C. Millar: None. S.M. Saenz: None. J. De Jesus-Gonzalez: None. H.A. Shaikh: None. A. Philis-Tsimikas: Advisory Panel; Dexcom, Inc., Lilly Diabetes, Novo Nordisk, Sanofi, Medtronic, Bayer Inc.

Funding

Merck (IIS#60691); National Institutes of Health (K12 TR004410); National Institutes of Health (KL2 TR001112); National Institutes of Health (P50MD017344)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.